Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

On June 30, 2025, Pyxis Oncology, Inc. (Nasdaq: PYXS) announced the grant of stock options for 246,238 shares of its common stock to four newly hired employees, as part of their 2022 Inducement Plan. This action is in compliance with Nasdaq Listing Rule 5635(c)(4), which allows companies to offer inducement grants to new employees. The stock options have a ten-year term and an exercise price of $1.10, aligning with the closing stock price on the grant date.

Of the total options awarded, 181,238 shares are set to vest over a four-year period, with 25% vesting after the first anniversary of the employees’ start date, followed by monthly vesting thereafter, contingent on continuous service with the company. Additionally, 65,000 options will vest fully on December 31, 2025, also depending on the recipient’s ongoing employment status.

Pyxis Oncology is a clinical-stage biopharmaceutical firm dedicated to developing innovative antibody-drug conjugates (ADCs) aimed at combating difficult-to-treat cancers. Its leading candidate, micvotabart pelidotin (MICVO), is currently undergoing Phase 1 clinical trials targeting recurrent and metastatic head and neck squamous cell carcinoma (R/M HNSCC). The company has ramped up its pipeline with a Phase 1/2 study combining MICVO with Merck’s KEYTRUDA® in patients with R/M HNSCC and other advanced solid tumors.

This announcement underscores Pyxis Oncology’s commitment to attracting top-tier talent as it advances its therapeutics designed to tackle complex oncology challenges. For further information, stakeholders and interested individuals can visit the company’s website or follow its updates on social media platforms.

On June 30, 2025, Pyxis Oncology, Inc. (Nasdaq: PYXS) announced the issuance of stock options to new employees under the 2022 Inducement Plan, in compliance with Nasdaq Listing Rule 5635(c)(4). This move signals management’s confidence in their strategic growth and human capital investment, critical for advancing their pipeline of next-generation antibody-drug conjugates (ADCs).

The granting of 246,238 stock options, especially with a ten-year exercise term and a price set at $1.10—the closing stock price of the day—can be seen as both an incentive for talent attraction and a method for aligning employee interests with shareholder value. The structured vesting schedule, featuring both annual and monthly components, encourages retention and long-term commitment from employees, essential for a clinical-stage biotech firm navigating complex trials.

Given Pyxis's focus on difficult-to-treat cancers, including their lead candidate, micvotabart pelidotin (MICVO), the upcoming Phase 1/2 studies will be pivotal. Investors should closely monitor the data from these trials, particularly the combination study of MICVO and Merck's KEYTRUDA in recurrent and metastatic head and neck squamous cell carcinoma (R/M HNSCC). Positive results could catalyze significant market momentum.

For potential investors, this news is a signal of sustained operational efforts in a high-stakes industry. While investing in clinical-stage companies can be risky due to high volatility and uncertain outcomes, Pyxis's strategic hires and ongoing clinical studies suggest a proactive approach to innovation that could yield substantial returns. As such, keeping an eye on clinical updates and the company’s performance against emerging competitive pressures is advisable for those considering an investment in PYXS. Continual assessment of market conditions and clinical data will be key in determining investment timing and positioning.